NCT06005649View on ClinicalTrials.gov

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Non-hodgkin Lymphoma

Interventions

BIOLOGICAL

HY004

"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells"